Feature | August 25, 2011

Occlutech Announces Closing of 15 Million Euro Financing

August 25, 2011 – Transcatheter structural heart occluder maker Occlutech said this week it closed a 15 million Euro investment in the company to accelerate its device development and bring it to market. The European company develops medical implants to treat structural heart disease such as atrial septal defects and patent foramen ovale (ASD and PFO) and left atrial appendage (LAA) occluders.

The funding follows a May 2011 German Supreme Court (BGH) decision to throw out a patent case against Occlutech filed by competitor AGA/St. Jude. AGA also filed claims in several other European countries, all of which have so far been favorable for Occlutech. The company said it intends to initiate litigation for substantial damages against AGA/St. Jude.

In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus artery (PDA) and ventricular septal defect (VSD) in addition to second-generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder and a new generation of stent grafts and cardiac valve intervention technologies are being developed.

The new funding came from an investment lead by Hong Kong-based Interlink Investments Ltd. and subscribed by investors as well as Occlutech distribution partners from Japan, Switzerland, Ireland, Austria and Turkey.

“This investment will allow us to accelerate our R&D and bring new, relevant products to the market in the near future,” said Tor Peters, Occlutech CEO. “In addition we expect substantial payments by AGA-St.  Jude as a result of litigation initiated by AGA in 2006 and culminating in a win for Occlutech in the German Supreme Court in 2011. The additional funding will allow us to aggressively respond to any new, similar litigation initiated in an attempt to divert our attention and resources from creating relevant products that support our customers in their quest to improve and save patient lives."

For more information: www.occlutech.com

Related Content

AtriCure, AtriClip PRO2 LAA Exclusion System, left atrial appendage, FDA clearance
Technology | Left Atrial Appendage (LAA) Occluders| April 29, 2016
April 29, 2016 — AtriCure Inc. announced U.S.
Sponsored Content | Videos | Left Atrial Appendage (LAA) Occluders| April 15, 2016
David Holmes, M.D., professor of medicine, Mayo Clinic College of Medicine and consultant, Department of Internal Med
aMAZE Trial enrollment, The Valley Hospital NJ, atrial fibrillation
News | Left Atrial Appendage (LAA) Occluders| March 16, 2016
The Valley Hospital in Ridgewood, N.J., is one of 15 U.S. sites currently enrolling patients in a research study...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart| February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
Watchman, left atrial appendage closure, LAA occluder
Technology | Left Atrial Appendage (LAA) Occluders| February 09, 2016
February 9, 2016 — Boston Scientific Corp.
transcatheter repair of a mitral valve paravalvular leak

Transcatheter repair of a surgical mitral replacement paravalvular leak with an Amplatzer Vascular Plug II.

Feature | Heart Valve Repair| February 08, 2016 | Dave Fornell
Off-label use of the St.
Ernest Shackleton, hole in the heart, Endurance 100th anniversary, Ian Calder
News | Structural Heart| January 20, 2016
On the 100th anniversary of the Endurance expedition to Antarctica led by Sir Ernest Shackleton, doctors writing in the...
Watchman, LAA closure device, cost effectiveness, VIvek Reddy, stroke reduction, study
News | Left Atrial Appendage (LAA) Occluders| January 06, 2016
A new study determined that the Watchman left atrial appendage closure device is more cost-effective than warfarin and...
watchman LAA occluder, LAAO registry

Implantation of the Boston Scientific Watchman LAA occluder.

News | Left Atrial Appendage (LAA) Occluders| December 29, 2015
December 29, 2015 — The American College of Cardiology (ACC) launched the new Left Atrial Appendage Occlusion (LAAO)
coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Overlay Init